Get started
Author

Satoshi Hara

Institution: Itami City Hospital
Observed institution: Itami City Hospital
ORCID: 0000-0003-1936-7163
Observed ORCID: 0000-0003-1936-7163
OpenAlex ID: A5058185880
A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2022 · Akira Sugimoto, Shingo Matsumoto, et al. · Clinical Cancer Research · 76
Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON)
2025 · Taiki Hakozaki, Kentaro Tanaka, et al. · Journal of Thoracic Oncology · 20
Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation
2025 · Shintaro Kanda, Seiji Niho, et al. · Clinical Cancer Research · 7
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial
2024 · Ryota Shibaki, Daichi Fujimoto, et al. · Lung Cancer · 7
Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)
2025 · Yoshihiko Sakata, Go Saito, et al. · Clinical Lung Cancer · 6
Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005)
2024 · Hayato Kawachi, Motohiro Tamiya, et al. · Clinical Lung Cancer · 5
PDF
Data from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2023 · Akira Sugimoto, Shingo Matsumoto, et al. · 1
Abstract 7919: Clinical, genomic, and therapeutic outcomes of lung squamous cell carcinoma with high LGR5 expression : A study from the LC-SCRUM-Asia database
2026 · Yu Tanaka, Shuji Murakami, et al. · Cancer Research
Supplementary Figures S1-S4 from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2025 · Akira Sugimoto, Shingo Matsumoto, et al.
PDF
Supplementary Tables S1-S4 from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2025 · Akira Sugimoto, Shingo Matsumoto, et al.
Corrigendum to ‘Gut Microbiota in Advanced NSCLC Receiving Chemoimmunotherapy: An Ancillary Biomarker Study From the Phase III Trial JCOG2007 (NIPPON)’ [Journal of Thoracic Oncology Vol. 20 No. 7 (2025) 912–927]
2025 · Taiki Hakozaki, Kentaro Tanaka, et al. · Journal of Thoracic Oncology
PDF
Supplementary Figure S3 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation
2025 · Shintaro Kanda, Seiji Niho, et al.
Table 1 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation
2025 · Shintaro Kanda, Seiji Niho, et al.
Supplementary Figure S2 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation
2025 · Shintaro Kanda, Seiji Niho, et al.
Supplementary Figure S1 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation
2025 · Shintaro Kanda, Seiji Niho, et al.
Supplementary Figure S4 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation
2025 · Shintaro Kanda, Seiji Niho, et al.
Figure 3 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation
2025 · Shintaro Kanda, Seiji Niho, et al.
Table 2 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation
2025 · Shintaro Kanda, Seiji Niho, et al.
Table 3 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation
2025 · Shintaro Kanda, Seiji Niho, et al.
Supplementary Data S1 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation
2025 · Shintaro Kanda, Seiji Niho, et al.
Figure 1 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation
2025 · Shintaro Kanda, Seiji Niho, et al.
Figure 2 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation
2025 · Shintaro Kanda, Seiji Niho, et al.
Supplementary Table S1 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation
2025 · Shintaro Kanda, Seiji Niho, et al.
Data from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation
2025 · Shintaro Kanda, Seiji Niho, et al.
Clinical-genomic characteristics in patients with EGFR-mutated non-small cell lung cancer harboring MET copy number gains after progression on EGFR-TKI: A report from LC-SCRUM-TRY.
2024 · Tsuyoshi Hirata, Hiroki Izumi, et al. · Journal of Clinical Oncology
PDF
Works count: 32
Citation count: 122
H-index: 5
I10-index: 2
Year
Topic
Type